Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well tivantinib works in treating
patients with relapsed, or relapsed and refractory multiple myeloma. Tivantinib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth.